Clinical progression of patients with COVID-19 in Lagos State, Nigeria

Author:

Mbagwu JP. C.,Olajugba J. O.,James-Okoro Paula-Peace,Blessing Obidike

Abstract

Abstract Background The majority of COVID-19 research has been devoted to characterizing the epidemiology and early clinical aspects of the virus. In Lagos, Nigeria, we looked at the temporal progression of COVID-19 patients. We included 1337 confirmed COVID-19 cases in our study from February 27th to March 27th 2020. Of the 1337 patients enrolled, the median age was 50 years old, and 800 (59.83%) were male while 537 (40.16%) were female. Method In symptomatic patients, the time from the beginning of signs to admission was 4 (2–7) days. Fever occurred in 217 (16.2%) while cough occurred in 211(15.78%) patients respectively. Patients were given 5–6 treatment, including nutrition support, supplementary oxygen, and antiviral medicines (e.g., Remdesivir, dexamethasone) in a limited percentage of cases. The assessed median period of infection in all patients was 10 days after the start of symptoms (95 confidential intervals [CIs]: 8–11 days). The duration of fever was slightly longer in patients admitted to intensive care units (ICU) than in those who were not (31 days versus 9 days, respectively, P < 0.003). Results On day 7 after the onset of symptoms, radiological deterioration of the original picture was found in 500 (37.39%) patients. On day 13, 154 of these patients (94.5%) showed signs of radiological improvement. The average time it took for upper respiratory tract samples to test negative for reverse transcriptase PCR was 10 days (90 percent confidence interval: 10–12 days). Virus clearance was more significant in ICU patients than in non-ICU patients (P < 0.003). Conclusions Community members should continue to adhere to the recommended methods of preventing the spread of COVID-19 infection and patients should seek care early to reduce the risk of mortality associated with the infection as rapidly as possible.

Publisher

Springer Science and Business Media LLC

Reference39 articles.

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. J Mol Virol. 2020;92:401–2.

2. Wang Y, Huang C, Li Z, Ren I, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel corona virus in Wuhan China. Lancet. 2020;395:497–506.

3. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J. Development and validation of clinical risk score to predict the occurrence critical illness in hospitalized patient with COVID-19. JAMA Intern Med. 2020;180:1–5.

4. Shrikushna SU, Quazi BA, Shubham S, Suraj T, Shreya W, Rohit B, Suraj S, Biyami KR. A review on Corona Virus (Covid-19). World Journal of Pharmaceutical and Life Sciences. 2020;6(4):109–15.

5. World Health Organization, Emergencies, Preparedness, Response. Pneumonia of unknown origin-China. 2020. Disease Outbreak News. 5 Available from” https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. (Accessed 22 May 2021).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3